Identification of a checkpoint modulator with synthetic lethality to p53 mutants
Naoki Harada(Osaka Prefecture University), Yuko Aoki, Fusao Makishima(Chugai Pharma (United States)), Yasushi Yoshimura, Yoshinori Watanabe, Masayuki Tsuchiya(Chugai Pharma (United States)), Hirofumi Sakumoto(Chugai Pharma (United States)), Keiko Nakanishi(Aichi Human Service Center), Makoto Nakanishi(The Cancer Institute Hospital)
Cited by 12
Related Papers
Navigating the DNA methylation landscape of cancer
|Trends in Genetics|2021|1k
Aberrant cell cycle checkpoint function and early embryonic death in <i>Chk1</i><sup>−/−</sup> mice
|Genes & Development|2000|469
Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription
|The EMBO Journal|2002|436